Literature DB >> 27789609

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

Jan-Willem C Alffenaar1, Simon Tiberi2, Roger K Verbeeck3, Scott K Heysell4, Martin P Grobusch5.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27789609      PMCID： PMC6394131          DOI： 10.1093/cid/ciw677

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  10 in total

Review 1.  Dried blood spots: a new tool for tuberculosis treatment optimization.

Authors:  D H Vu; J W C Alffenaar; P M Edelbroek; J R B J Brouwers; D R A Uges
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

2.  Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs.

Authors:  Scott K Heysell; Suporn Pholwat; Stellah G Mpagama; Saumu J Pazia; Happy Kumburu; Norah Ndusilo; Jean Gratz; Eric R Houpt; Gibson S Kibiki
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

3.  End TB with precision treatment!

Authors:  Evelien P M van der Burgt; Marieke G G Sturkenboom; Mathieu S Bolhuis; Onno W Akkerman; Jos G W Kosterink; Wiel C M de Lange; Frank G J Cobelens; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Eur Respir J       Date:  2016-02       Impact factor: 16.671

4.  Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.

Authors:  Samiksha Ghimire; Mathieu S Bolhuis; Marieke G G Sturkenboom; Onno W Akkerman; Wiel C M de Lange; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Eur Respir J       Date:  2016-03-17       Impact factor: 16.671

5.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Authors:  Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

Review 6.  Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Marlanka A Zuur; Mathieu S Bolhuis; Richard Anthony; Alice den Hertog; Tridia van der Laan; Bob Wilffert; Wiel de Lange; Dick van Soolingen; Jan-Willem C Alffenaar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-03-24       Impact factor: 4.481

7.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

8.  The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.

Authors:  P R Donald; F A Sirgel; A Venter; D P Parkin; H I Seifart; B W van de Wal; C Werely; P D van Helden; J S Maritz
Journal:  Clin Infect Dis       Date:  2004-10-25       Impact factor: 9.079

9.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

10.  NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Authors:  Junichi Azuma; Masako Ohno; Ryuji Kubota; Soichiro Yokota; Takayuki Nagai; Kazunari Tsuyuguchi; Yasuhisa Okuda; Tetsuya Takashima; Sayaka Kamimura; Yasushi Fujio; Ichiro Kawase
Journal:  Eur J Clin Pharmacol       Date:  2012-11-14       Impact factor: 2.953
  10 in total
  11 in total

1.  Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.

Authors:  Antonia Morita I Saktiawati; Marcel Harkema; Althaf Setyawan; Yanri W Subronto; Ymkje Stienstra; Rob E Aarnoutse; Cecile Magis-Escurra; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar; Marieke G G Sturkenboom
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients.

Authors:  Simone H J van den Elsen; Marieke G G Sturkenboom; Onno W Akkerman; Katerina Manika; Ioannis P Kioumis; Tjip S van der Werf; John L Johnson; Charles Peloquin; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

3.  Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios.

Authors:  Hannah Yejin Kim; Kenneth C Byashalira; Scott K Heysell; Anne-Grete Märtson; Stellah G Mpagama; Prakruti Rao; Marieke G G Sturkenboom; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

4.  Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

Authors:  Simone H J van den Elsen; Marieke G G Sturkenboom; Natasha Van't Boveneind-Vrubleuskaya; Alena Skrahina; Tjip S van der Werf; Scott K Heysell; Stellah Mpagama; Giovanni B Migliori; Charles A Peloquin; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

5.  Therapeutic Drug Monitoring: The Need for Practical Guidance.

Authors:  Jan-Willem C Alffenaar; Scott K Heysell; Stellah G Mpagama
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

6.  Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.

Authors:  Daan J Touw; Giovanni B Migliori; Jan-Willem Alffenaar; Simone Hj van den Elsen; Marieke Gg Sturkenboom; Onno Akkerman; Linda Barkane; Judith Bruchfeld; Geoffrey Eather; Scott K Heysell; Henadz Hurevich; Liga Kuksa; Heinke Kunst; Johanna Kuhlin; Katerina Manika; Charalampos Moschos; Stellah G Mpagama; Marcela Muñoz Torrico; Alena Skrahina; Giovanni Sotgiu; Marina Tadolini; Simon Tiberi; Francesca Volpato; Tjip S van der Werf; Malcolm R Wilson; Joaquin Zúñiga
Journal:  BMJ Open       Date:  2020-06-16       Impact factor: 2.692

7.  Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review.

Authors:  Nurul Cholifah Lutfiana; Job F M van Boven; Muhammad Asim Masoom Zubair; Michelle J Pena; Jan-Willem C Alffenaar
Journal:  Br J Clin Pharmacol       Date:  2019-05-17       Impact factor: 4.335

8.  Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.

Authors:  Jan-Willem C Alffenaar; Tawanda Gumbo; Kelly E Dooley; Charles A Peloquin; Helen Mcilleron; Andre Zagorski; Daniela M Cirillo; Scott K Heysell; Denise Rossato Silva; Giovanni Battista Migliori
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

9.  A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Authors:  Alper Daskapan; Lusiana R Idrus; Maarten J Postma; Bob Wilffert; Jos G W Kosterink; Ymkje Stienstra; Daniel J Touw; Aase B Andersen; Adrie Bekker; Paolo Denti; Agibothu K Hemanth Kumar; Kidola Jeremiah; Awewura Kwara; Helen McIlleron; Graeme Meintjes; Joep J van Oosterhout; Geetha Ramachandran; Neesha Rockwood; Robert J Wilkinson; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

10.  A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva.

Authors:  Jan-Willem C Alffenaar; Erwin M Jongedijk; Claudia A J van Winkel; Margaretha Sariko; Scott K Heysell; Stellah Mpagama; Daan J Touw
Journal:  J Antimicrob Chemother       Date:  2021-01-19       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.